Cargando…
Resolution of Crizotinib-Associated Fulminant Hepatitis following Cessation of Treatment
Targeted cancer treatments offer the prospect of precise inhibition of tumor growth without the untoward off-target toxicity of traditional chemotherapies. Still, unintended, often idiosyncratic side effects, such as drug-induced liver injury, can occur. We discuss the case of a 26-year-old female w...
Autores principales: | Charville, Gregory W., Padda, Sukhmani K., Sibley, Richard K., Puthillath, Ajithkumar, Kwo, Paul Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098865/ https://www.ncbi.nlm.nih.gov/pubmed/30155324 http://dx.doi.org/10.1155/2018/3413592 |
Ejemplares similares
-
Crizotinib-Induced Fulminant Hepatic Failure: A Rare Adverse
Event
por: Adhikari, Narayan, et al.
Publicado: (2016) -
Targeted therapies in the management of colorectal carcinoma: role of bevacizumab
por: Puthillath, Ajithkumar, et al.
Publicado: (2009) -
Navigating the Landscape of Molecular Testing and Targeted Treatment of Non–Small Cell Lung Cancer
por: Padda, Sukhmani K., et al.
Publicado: (2016) -
Successful Treatment of Crizotinib-Induced Fulminant Liver Failure: A Case Report and Review of Literature
por: Kreitman, Kyle, et al.
Publicado: (2020) -
Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination
por: Rolfes, Leoni, et al.
Publicado: (2019)